Welcome to our dedicated page for Kane Biotech news (Ticker: KNBIF), a resource for investors and traders seeking the latest updates and insights on Kane Biotech stock.
Kane Biotech Inc. (KNBIF, TSX-V: KNE) generates news primarily around its wound care biotechnology activities, especially the development and clinical use of its revyve ae Antimicrobial Wound Gel and Wound Gel Spray. Company updates frequently highlight how these products are designed to disrupt biofilms and address wound bacteria, which Kane Biotech identifies as key contributors to antibiotic resistance and complex wound outcomes.
News releases often cover regulatory milestones, such as FDA 510(k) clearances for revyve Antimicrobial Wound Gel and Spray, Health Canada approvals for the gel and spray, and the submission of a 510(k) application for revyve Antimicrobial Wound Cleanser. Investors and clinicians can also follow announcements about clinical and pre-clinical data, including case series in diabetic foot ulcers, burn wounds, chronic radiation-induced ulcers, venous leg ulcers, and other challenging wound types.
Kane Biotech regularly reports participation in wound care and burn conferences, where it presents data on healing trajectories, infection control, and biofilm management using revyve products. These events include meetings such as the Symposium on Advanced Wound Care, Diabetic Foot Conference, Southern Region Burn Conference, Innovations in Wound Healing, and other specialized gatherings.
In addition, the company issues news on financing and corporate developments, including private placement offerings, financial results, board and committee changes, and interactions with funding partners. For readers tracking KNBIF, this news page provides a centralized view of Kane Biotech’s scientific, regulatory, clinical, and corporate announcements related to its wound care biotechnology focus.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) has announced it will release its third quarter 2024 financial results after market close on November 28, 2024. The company will hold a conference call to discuss the results and business developments on December 3, 2024 at 4:30 p.m. ET. Participants are required to register for the call in advance, with recommended joining time being 10 minutes before the event. A webcast will be available on Kane Biotech's website in the Investor section.
Kane Biotech has received Health Canada approval for its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This regulatory milestone enables the company to immediately begin marketing and selling the product in the Canadian market. The approval represents a significant step in Kane Biotech's strategic execution plan.
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF) has released a video featuring President & CEO Marc Edwards and Executive Chair Dr. Robert Huizinga discussing the recently announced FB Dermatology S.R.L. acquisition. The video presentation covers FB Dermatology's technology, product portfolio, market presence, and regulatory approvals, along with potential synergies between the two companies. This follows the initial acquisition announcement made on November 12, 2024.
Kane Biotech (KNBIF) has entered into a binding term sheet to acquire FB Dermatology, an Italian company with operations in Italy and Australia. The acquisition includes FB's FLETECH technology portfolio, featuring products like LumiHeal®, Kleresca®, and Lumixa® for wound care and dermatology applications. The purchase price includes $200,000 in cash at closing, 6 million Kane shares, 6 million warrants at $0.25, and potential future payments of $920,000 and $1,380,000 at 18 and 36 months respectively. The transaction is expected to close by January 31, 2025, expanding Kane's global commercial reach and strengthening its wound care portfolio.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its participation in a multinational corporate collaboration project. The company is receiving advisory services and up to $75,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for this initiative.
The project aims to develop a Proof-of-Concept for Kane's DispersinB® Wound Gel. Kane will collaborate with one of the world's largest wound care companies over a six-month period. This collaboration is expected to accelerate the development of the DispersinB® Wound Gel technology.
In addition to this project, Kane Biotech recently secured advisory services and up to $200,000 in research and development funding from NRC IRAP to support the development of three additional products based on the company's revyve™ Antimicrobial Wound Gel technology.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its participation in several upcoming wound care conferences to showcase its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray products. The company will attend:
- Symposium on Advanced Wound Care (SAWC) in Las Vegas, Nevada (October 2-5, 2024)
- Wounds Canada National Hybrid Conference in London, Ontario (October 17-19, 2024)
- Canadian Burn Conference in Niagara-on-the-Lake, Ontario (October 18-20, 2024)
- Gulf Diabetic Foot Conference in Kuwait City, Kuwait (November 15-16, 2024)
At these events, Kane Biotech will present research on the antibiofilm properties of its products and have booth presence to demonstrate the scientific benefits of the revyve™ product line to wound care practitioners.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced the exercise of 5 million warrants at an exercise price of $0.10 per common share, resulting in total proceeds of $500,000. The company's President & CEO, Marc Edwards, stated that the shares are being held by long-term supporters of Kane. The proceeds from these warrant exercises will be utilized for general working capital purposes, providing the company with additional financial resources for its operations.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced its second quarter 2024 financial results, highlighting a significant $10.4 million gain from the sale of STEM. Key financial highlights include:
- License and royalty income increased by 74% to $299,992
- Product and services revenue rose by 5% to $510,360
- Total revenue grew by 23% to $810,352
- Gross profit increased by 41% to $464,453
- Net income of $9,201,830 compared to a net loss of ($967,905) in Q2 2023
The company also reported several recent developments, including new distribution agreements, MDSAP Quality Certification, FDA removal of usage limitations on revyve™ Antimicrobial Wound Gel, and new funding from NRC IRAP for product development.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has announced the publication of a new review article on DispersinB® in the journal Pathogens. The article, authored by Dr. Jeffrey B. Kaplan, highlights the enzyme's broad-spectrum antibiofilm activity against over 25 bacterial species. Kane Biotech is also presenting research on its revyve™ Antimicrobial Wound Gel Spray at the Military Health System Research Symposium and the Symposium on Advance Wound Care. These presentations showcase the company's commitment to advancing biofilm science and developing potential treatments for chronic wound infections.
Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) has signed a three-year distribution agreement with Qatar Datamation Systems (QDS) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market. This marks Kane's second distribution agreement in the Middle East and fourth overall for revyve™.
The company has previously secured distribution agreements for revyve™ in the United Arab Emirates, United States, Colombia, Costa Rica, and Panama. Kane Biotech also plans to commercialize revyve™ in Canada following its recent ISO 13485:2016 Medical Device Single Audit Program (MDSAP) certification.